Regeneron (REGN) Tops Q1 EPS by 47c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Reports First Quarter 2020 Financial and Operating Results
May 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., May 5, 2020 /PRNewswire/ --
First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019(4) First quarter EYLEA® U.S. net sales increased 9% to $1.17 billion versus first quarter 2019 First quarter Dupixent® global net sales(2), which are recorded by Sanofi, increased 129% to $855 million versus first quarter 2019 First quarter 2020 GAAP diluted EPS was $5.43 and non-GAAP diluted EPS(1) was $6.60 Libtayo® Phase 3 trial in first-line non-small cell lung cancer stopped early due to positive overall survival benefit with regulatory submissions planned later this year Libtayo showed... More